A carregar...
555. Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States
BACKGROUND: Raltegravir (RAL) 400 mg twice-daily (RAL BID) has been an integral part of antiretroviral therapy (ART) in both ART naïve and experienced HIV-1 infected patients for the last decade. In 2017, RAL 1,200 mg (2 × 600 mg), a once-daily formulation (RAL QD) was approved. The objective of thi...
Na minha lista:
| Publicado no: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6255467/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.563 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|